| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/21/2006 | CA2152486C Anticonvulsant sorbopyranose sulfamates |
| 02/21/2006 | CA2116165C Substituted benzenesulfonylureas and -thioureas - processes for their preparation and their use as pharmaceuticals |
| 02/21/2006 | CA2110443C Guanidinealkyl-1,1-bisphosphonic acid derivatives, process for their preparation and their use |
| 02/21/2006 | CA2065986C 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1h-indoles, intermediates and a process for their preparation, and their use as medicaments |
| 02/19/2006 | CA2505656A1 Process for the preparation of topiramate |
| 02/17/2006 | CA2478138A1 Cxcl10-based diagnosis and treatment of respiratory illnesses |
| 02/16/2006 | WO2006017861A2 Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists |
| 02/16/2006 | WO2006017854A2 Compositions and methods for determining and predicting treatment responses for depression and anxiety |
| 02/16/2006 | WO2006017852A2 Pharmaceutical compositions for controlled release delivery of biologically active compounds |
| 02/16/2006 | WO2006017844A1 NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) |
| 02/16/2006 | WO2006017823A2 Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors |
| 02/16/2006 | WO2006017816A2 Product and process for inhibition of biofilm development |
| 02/16/2006 | WO2006017768A2 Muscarinic acetylcholine receptor antagonists |
| 02/16/2006 | WO2006017767A2 Muscarinic acetylcholine receptor antagonists |
| 02/16/2006 | WO2006017761A2 Epothilone analogues as therapeutic agents |
| 02/16/2006 | WO2006017692A2 Novel fenofibrate formulations and related methods of treatment |
| 02/16/2006 | WO2006017672A2 2, 8-disubstituted naphthyridine derivatives |
| 02/16/2006 | WO2006017650A2 Iron chelators for treating radiocontrast-associated renal dysfunction |
| 02/16/2006 | WO2006017627A2 Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance |
| 02/16/2006 | WO2006017614A1 Use of n-desmethylclozapine to treat human neuropsychiatric disease |
| 02/16/2006 | WO2006017590A2 Use of methyl pyruvate for the purpose of reducing weight gain in mammals |
| 02/16/2006 | WO2006017542A1 Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
| 02/16/2006 | WO2006017524A2 Preventing pathological increases in the rate of nerve cell suicide in immature nervous systems |
| 02/16/2006 | WO2006017505A2 Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases |
| 02/16/2006 | WO2006017494A2 Inhibition of anaerobic glucose metabolism |
| 02/16/2006 | WO2006017491A2 Methods and compositions to reduce tissue irritation in parenteral formulations |
| 02/16/2006 | WO2006017468A2 Antibacterial agents |
| 02/16/2006 | WO2006017443A2 Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds |
| 02/16/2006 | WO2006017409A2 1,3-disubstituted heteroaryl nmda/nr2b antagonists |
| 02/16/2006 | WO2006017406A1 Cyanoamidine p2x7 antagonists for the treatment of pain |
| 02/16/2006 | WO2006017347A2 Opthalmic compositions and methods for treating ophthalmic conditions |
| 02/16/2006 | WO2006017320A2 Compositions and methods for myogenesis of fat-derived stem cells expressing telomerase and myocardin |
| 02/16/2006 | WO2006017317A2 Method for the treatment of disease |
| 02/16/2006 | WO2006017295A2 Tetrapeptide analogs |
| 02/16/2006 | WO2006017281A1 Methods for inducing anti-anxiety and calming effects in animals and humans |
| 02/16/2006 | WO2006017250A2 Sixteen-membered macrolide antiinfective agents |
| 02/16/2006 | WO2006017215A2 Histone deacetylase inhibitors |
| 02/16/2006 | WO2006017188A2 Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| 02/16/2006 | WO2006017171A2 Methods of diagnosing & treating obesity, diabetes and insulin resistance |
| 02/16/2006 | WO2006017124A2 Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases |
| 02/16/2006 | WO2006017054A2 Tricyclic-heteroaryl compounds useful as kinase inhibitors |
| 02/16/2006 | WO2006017052A1 Process for the preparation of a1 adenosine receptor agonists |
| 02/16/2006 | WO2006017044A2 Topical antiviral formulations |
| 02/16/2006 | WO2006016904A2 Activators of hexosamine biosynthesis as inhibitors of injury induced by ischemia or hemorrhagic shock |
| 02/16/2006 | WO2006016903A2 1, 2,4-trioxanes and 1, 2, 4-trioxepanes |
| 02/16/2006 | WO2006016828A2 Use of alpha ketoglutarate for treating alzheimer, parkinson |
| 02/16/2006 | WO2006016707A2 Pyrazolone compounds for treating cerebrovascular disorders |
| 02/16/2006 | WO2006016695A1 Preventive and/or remedy for hyperkalemia containing ep4 agonist |
| 02/16/2006 | WO2006016685A1 Method for producing capsinoid-containing microcapsule |
| 02/16/2006 | WO2006016682A1 Ameliorant for blood vessel elasticity and use thereof |
| 02/16/2006 | WO2006016681A2 Crp lowering agent |
| 02/16/2006 | WO2006016680A1 Hydroxyamide compounds having activity as inhibitors of histone deacetylase (hdac) |
| 02/16/2006 | WO2006016657A1 Drug for treating or preventing hcv infection |
| 02/16/2006 | WO2006016637A1 Novel cyclic aminobenzoic acid derivative |
| 02/16/2006 | WO2006016602A1 Nateglinide-containing preparation reduced in bitterness |
| 02/16/2006 | WO2006016574A1 ANTINEOPLASTIC AGENT APPLYING RNAi |
| 02/16/2006 | WO2006016530A1 Transnasal composition having immediate action and high absorbability |
| 02/16/2006 | WO2006016278A1 Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders |
| 02/16/2006 | WO2006016247A2 Lysis/resealing process and device for incorporating an active ingredient in erythrocytes |
| 02/16/2006 | WO2006016245A1 Muscarinic receptor antagonists |
| 02/16/2006 | WO2006016218A1 Aryl or heteroaryl carbonyl derivatives derivatives useful as vanilloid receptor 1 (vr1) antagonists |
| 02/16/2006 | WO2006016192A2 Combination therapy with nk3 receptor antagonists for the treatment of schizophrenia |
| 02/16/2006 | WO2006016178A1 Enantioselective process |
| 02/16/2006 | WO2006016152A1 Anti-inflammatory agents |
| 02/16/2006 | WO2006016139A1 Composition for promoting vascular smooth muscle relaxation |
| 02/16/2006 | WO2006016093A1 Immunomodulating oxopyrrazolocinnolines as cd80 inhibitors |
| 02/16/2006 | WO2006016069A1 Ruthenium complexes for treating cancers |
| 02/16/2006 | WO2006016067A2 Pyrido-pyrido pyrimidine derivatives, preparation thereof, therapeutic use thereof for treating cancer |
| 02/16/2006 | WO2006016062A1 Multitherapy against cancer |
| 02/16/2006 | WO2006016040A1 Compositions containing nicorandil, preparation method and use |
| 02/16/2006 | WO2006016039A1 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof |
| 02/16/2006 | WO2006015970A2 Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic |
| 02/16/2006 | WO2006015944A2 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
| 02/16/2006 | WO2006015943A2 Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| 02/16/2006 | WO2006015942A1 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| 02/16/2006 | WO2006015930A1 Phenol derivatives |
| 02/16/2006 | WO2006015870A1 Tetrahydro-naphthalene derivatives as glucocorticoid receptor modulators |
| 02/16/2006 | WO2006015861A2 Drop preparations comprising dimetindene |
| 02/16/2006 | WO2006015860A2 Pyrazole derivatives for treating conditions mediated by activation of the adenosine a2b or a3 receptor |
| 02/16/2006 | WO2006015775A2 Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders |
| 02/16/2006 | WO2006015715A1 Novel uses of 2-phenyl-substituted imidazotriazinone derivatives |
| 02/16/2006 | WO2006015590A2 Novel formulation for l-tryptophane comprising carbidopa/benserazide |
| 02/16/2006 | WO2005121160A3 11, 12 cyclic thiocarbamate macrolide antibacterial agents |
| 02/16/2006 | WO2005121097A3 Pyrazole derivatives, compositions containing such compounds and methods of use |
| 02/16/2006 | WO2005120521A3 Methods of treating cancer with 8-chloro-adenosine |
| 02/16/2006 | WO2005120476A3 Novel use of peptide compounds for treating amyotrophic lateral sclerosis |
| 02/16/2006 | WO2005117863A3 Non-steroid anti-inflammatory agents with vitamins, minerals, and dietary supplements for the prevention and treatment of primary, secondary and tertiary cancer |
| 02/16/2006 | WO2005115421A8 Use of a compound comprising d-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases |
| 02/16/2006 | WO2005115378B1 Compositions comprising flavonoids and tocotrienols and methods thereof |
| 02/16/2006 | WO2005115377B1 Functional foods comprising flavonoids and tocotrienols and methods thereof |
| 02/16/2006 | WO2005112916A3 Bis-aryl sulfonamides |
| 02/16/2006 | WO2005112538A3 Use of adrenergic n-phenylpiperazine antagonists, pharmaceutical compositions containing them, and methods of preparing them. |
| 02/16/2006 | WO2005110414A3 Hiv integrase inhibitors |
| 02/16/2006 | WO2005110409A3 Tetrahydropyranyl cyclopentyl 1-substituted and 1,1-disubstituted tetrahydroisoquinoline modulators of chemokine receptor activity |
| 02/16/2006 | WO2005108387A3 Cytokine inhibitors |
| 02/16/2006 | WO2005105739A3 Cyanopyrrole containing cyclic carbamate and thiocarbamate biaryls and methods for preparing the same |
| 02/16/2006 | WO2005105064A3 Modulators of frat-lrp interaction in the treatment of bone-related diseases |
| 02/16/2006 | WO2005097799A8 Pyrazolo`4,3-d! pyrimidines |
| 02/16/2006 | WO2005097137A3 Advanced quinazoline based protein kinase inhibitors |
| 02/16/2006 | WO2005097135A3 Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives |